59 related articles for article (PubMed ID: 6380075)
1. Unaltered lipoprotein and carbohydrate metabolism during treatment with contraceptive subdermal implants containing ST-1435.
Odlind V; Lithell H; Selinus I; Vessby B
Ups J Med Sci; 1984; 89(2):151-8. PubMed ID: 6380075
[TBL] [Abstract][Full Text] [Related]
2. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
[TBL] [Abstract][Full Text] [Related]
3. Concentration-dependent mechanisms of ovulation inhibition by the progestin ST-1435.
Lähteenmäki PL; Lähteenmäki P
Fertil Steril; 1985 Jul; 44(1):20-4. PubMed ID: 3924666
[TBL] [Abstract][Full Text] [Related]
4. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
[TBL] [Abstract][Full Text] [Related]
5. Serum lipids, blood pressure, body weight, and serum chemistry in women using subcutaneous contraceptive implants releasing the progestin ST 1435.
Laurikka-Routti M
Obstet Gynecol; 1992 Nov; 80(5):855-9. PubMed ID: 1407928
[TBL] [Abstract][Full Text] [Related]
6. Lipid and carbohydrate metabolism in premenopausal women given subdermal estradiol implants.
Crook D; Montgomery JC; Godsland IF; Devenport M; Marenah CB; Studd JW; Wynn V
Horm Metab Res; 1991 Apr; 23(4):174-7. PubMed ID: 1874476
[TBL] [Abstract][Full Text] [Related]
7. The effects of nomegestrol acetate subdermal implant (Uniplant) on carbohydrate metabolism, serum lipoproteins and on hepatic function in women.
Barbosa I; Coutinho E; Athayde C; Ladipo O; Olsson SE; Ulmsten U
Contraception; 1995 Aug; 52(2):111-4. PubMed ID: 8536447
[TBL] [Abstract][Full Text] [Related]
8. Metabolic effects of two low-dose triphasic oral contraceptives containing ethinyl estradiol and levonorgestrel or gestodene.
Lepot MR; Gaspard UJ
Int J Fertil; 1987; 32 Suppl():15-20. PubMed ID: 2906343
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of a contraceptive vaginal ring releasing norethindrone and estradiol: ovarian function, bleeding control and lipoprotein patterns.
Victor A; Lithell H; Selinus I; Vessby B
Ups J Med Sci; 1984; 89(2):179-88. PubMed ID: 6380076
[TBL] [Abstract][Full Text] [Related]
10. A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry.
Laurikka-Routti M; Haukkamaa M; Heikinheimo O
Contraception; 1990 Jul; 42(1):111-20. PubMed ID: 2387151
[TBL] [Abstract][Full Text] [Related]
11. Lipid metabolic studies in oophorectomized women: effects induced by two different estrogens on serum lipids and lipoproteins.
Silfverstolpe G; Gustafson A; Samsioe G; Svanborg A
Gynecol Obstet Invest; 1980; 11(3):161-9. PubMed ID: 7439809
[TBL] [Abstract][Full Text] [Related]
12. Contraception with subcutaneous capsules containing ST-1435. Pituitary and ovarian function and plasma levels of ST-1435.
Lähteenmäki P; Weiner E; Lähteenmäki P; Johansson E; Luukkainen T
Contraception; 1981 Jan; 23(1):63-75. PubMed ID: 7471746
[TBL] [Abstract][Full Text] [Related]
13. Effects of continuous levonorgestrel treatment (subcutaneous capsules) on the lipoprotein and carbohydrate metabolism in fertile women.
Lithell H; Weiner E; Vessby B; Johansson ED
Ups J Med Sci; 1983; 88(2):103-8. PubMed ID: 6417867
[TBL] [Abstract][Full Text] [Related]
14. A contraceptive subdermal implant releasing the progestin ST-1435: ovarian function, bleeding patterns, and side effects.
Laurikka-Routti M; Haukkamaa M
Fertil Steril; 1992 Dec; 58(6):1142-7. PubMed ID: 1459263
[TBL] [Abstract][Full Text] [Related]
15. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.
Skouby SO; Endrikat J; Düsterberg B; Schmidt W; Gerlinger C; Wessel J; Goldstein H; Jespersen J
Contraception; 2005 Feb; 71(2):111-7. PubMed ID: 15707560
[TBL] [Abstract][Full Text] [Related]
16. Desogestrel and gestodene in oral contraceptives: 12 months' assessment of carbohydrate and lipoprotein metabolism.
Petersen KR; Skouby SO; Pedersen RG
Obstet Gynecol; 1991 Oct; 78(4):666-72. PubMed ID: 1833682
[TBL] [Abstract][Full Text] [Related]
17. Study of the effects of the implantable contraceptive Norplant on lipid and lipoprotein metabolism. UN Development Programme/UN Population Fund/WHO/World Bank, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-Acting Systemic Agents for Fertility Regulation.
Contraception; 1999 Jan; 59(1):31-45. PubMed ID: 10342084
[TBL] [Abstract][Full Text] [Related]
18. The clinical and biochemical effects of two combination oral contraceptive agents.
Sapire KE; Berger GM; Maritz JS
S Afr Med J; 1991 Apr; 79(7):376-9. PubMed ID: 1826569
[TBL] [Abstract][Full Text] [Related]
19. A prospective study of insulin sensitivity and glucose metabolism in women using a continuous subdermal levonorgestrel implant system.
Harper MA; Meis PJ; Steele L
J Soc Gynecol Investig; 1997; 4(2):86-9. PubMed ID: 9101467
[TBL] [Abstract][Full Text] [Related]
20. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study.
Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C
Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
